GPVI seems an attractive target in stroke since (i) it's only expressed on platelets, (ii) patients with a GPVI deficiency have no or mild bleeding phenotype (112), (iii) GPVI inhibition leads to a significant reduction of thrombus formation (113, 114), (iv) a novel humanized Fab anti GPVI (ACT017) in healthy donors didn't show bleeding complications (15). This evidence concerns the gene GP6 and Stroke.